4563.T
AnGes,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 39.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 908.0M | 874.0M | 643.0M | 152.0M | 67.0M |
| Cost of Revenue | 562.0M | 553.7M | 395.9M | 133.5M | 93.9M |
| Gross Profit | 345.9M | 320.3M | 247.1M | 18.5M | (26.9M) |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 2.0B | 1.9B | 5.6B | 5.8B | 5.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.0B | 1.9B | 5.6B | 5.8B | 5.3B |
| Cost and Expenses | 6.3B | 6.0B | 9.8B | 12.1B | 16.4B |
| Operating Income (EBIT) | (5.4B) | (5.1B) | (9.1B) | (12.0B) | (16.3B) |
| Non-Operating | |||||
| Interest Income | 17.6M | 14.9M | 4.4M | 8.4M | 1.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 225.1M | (143.4M) | 1.6B | 6.3B | 1.7B |
| Non-Operating Income (excl Interest) | 473.3M | 114.5M | 1.6B | 6.3B | 1.7B |
| EBT (Pre-Tax Income) | (5.1B) | (5.2B) | (27.6B) | (7.5B) | (14.7B) |
| Income Tax Expense | (151.1M) | (113.3M) | 485.3M | (33.8M) | (2.2M) |
| Bottom Line | |||||
| Net Income | (5.0B) | (5.1B) | (28.1B) | (7.4B) | (14.7B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.0B) | (5.1B) | (28.1B) | (7.4B) | (14.7B) |
| Per Share | |||||
| Basic EPS | (¥14) | (¥14) | (¥120) | (¥39) | (¥94) |
| Diluted EPS | (¥14) | — | — | — | — |
| Revenue Per Share | ¥2 | ¥2 | ¥3 | ¥1 | ¥0 |
| Shares | |||||
| Basic Shares Outstanding | 395.2M | 354.8M | 235.3M | 189.3M | 156.1M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | (2.7B) | (5.1B) | (9.1B) | (11.9B) | (16.3B) |
| D&A | 53.8M | 53.8M | 48.9M | 27.9M | 18.2M |
| EBIT | (5.4B) | (5.1B) | (9.1B) | (12.0B) | (16.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026